Fmr LLC Has $150.55 Million Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

FMR LLC raised its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 0.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,836,040 shares of the company's stock after purchasing an additional 23,436 shares during the period. FMR LLC owned approximately 9.67% of Immunocore worth $150,546,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of IMCR. Exchange Traded Concepts LLC grew its position in shares of Immunocore by 40.4% during the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock valued at $158,000 after purchasing an additional 1,461 shares in the last quarter. Tidal Investments LLC bought a new stake in shares of Immunocore during the first quarter valued at approximately $423,000. Connective Portfolio Management LLC bought a new position in Immunocore in the third quarter worth approximately $218,000. DNB Asset Management AS raised its stake in Immunocore by 35.0% in the second quarter. DNB Asset Management AS now owns 7,211 shares of the company's stock worth $244,000 after buying an additional 1,868 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Immunocore by 69.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock worth $231,000 after purchasing an additional 3,053 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Stock Down 1.5 %

IMCR traded down $0.47 during trading on Wednesday, hitting $31.75. The company had a trading volume of 264,641 shares, compared to its average volume of 505,191. The company has a market cap of $1.59 billion, a PE ratio of -33.42 and a beta of 0.73. The business has a 50-day moving average of $32.30 and a 200-day moving average of $36.15. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore Holdings plc has a 1-year low of $29.72 and a 1-year high of $76.98.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.50. The company had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company's revenue for the quarter was up 23.7% on a year-over-year basis. During the same period last year, the firm posted ($0.59) EPS. As a group, analysts forecast that Immunocore Holdings plc will post -0.94 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IMCR. Morgan Stanley dropped their price objective on shares of Immunocore from $80.00 to $74.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Oppenheimer reiterated an "outperform" rating and issued a $89.00 price objective (up previously from $87.00) on shares of Immunocore in a research report on Friday, August 9th. UBS Group assumed coverage on shares of Immunocore in a research report on Thursday, October 24th. They set a "sell" rating and a $24.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a report on Thursday, October 24th. Finally, Needham & Company LLC cut their price objective on shares of Immunocore from $78.00 to $71.00 and set a "buy" rating for the company in a report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Immunocore has a consensus rating of "Moderate Buy" and a consensus target price of $69.18.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.